A Prospective, Observational, Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb (Fimasartan) During 1 Year Among 20 and Older Diagnosed With Essential Hypertension

Trial Profile

A Prospective, Observational, Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb (Fimasartan) During 1 Year Among 20 and Older Diagnosed With Essential Hypertension

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Fimasartan (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions
  • Sponsors Boryung Pharmaceutical
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
    • 25 Jul 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Sep 2017.
    • 21 Sep 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top